Prescription drug · BLA

Skyrizi (Risankizumab-rzaa) NDC 0074-7040

Kit · AbbVie Inc.

NDC codes

FDA NDC Directory
Product NDC (as listed)0074-7040Labeler and product segments. Claims need a package NDC.
Product NDC at billing width00074-7040Add the package segment from the table below.
Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC11-digit (billing)PackageCopy
0074-7040-02000747040022 CARTON in 1 CARTON (0074-7040-02) / 1 KIT in 1 CARTON * 1 mL in 1 SYRINGE, GLASS (0074-7032-01)Marketed from Mar 4, 2024

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary)
Skyrizi
Generic name (nonproprietary)
risankizumab-rzaa
Dosage form
Kit
Labeler
AbbVie Inc.NDC labeler code 0074
Product type
Prescription drug
Marketing category
BLA — Biologics License ApplicationApplication BLA 761105
Marketing start
Listing expires
Identifiers
Product ID 0074-7040_388f783d-f41e-4f04-bf64-ec637fe05bdfSPL ID 388f783d-f41e-4f04-bf64-ec637fe05bdfSPL set ID 7148c8eb-b39e-e20a-6494-a6df82392858RxCUI 797544, 2166136, 2166137, 2166142, 2166143, 2540692, 2540695, 2540698, 2540699, 2604618, 2604622, 2604625, 2604628, 2613758, 2613759, 2632994, 2632997, 2632999, 2633000, 2633001, 2633002, 2723331, 2723332, 2745412, 2745415UNII 90ZX3Q3FR7

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N400074704002 followed by a unit qualifier and the quantity

Package 00074-7040-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective .

Indications (excerpt from the label)

SKYRIZI is an interleukin-23 antagonist indicated for the treatment of: moderate-to-severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy. ( 1.1 ) active psoriatic arthritis in adults and pediatric patients 6 years of age and older. ( 1.2 ) moderately to severely active Crohn's disease in adults. ( 1.3 ) moderately to severely active ulcerative colitis in adults. ( 1.4 ) 1.1 Plaque Psoriasis SKYRIZI ® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy. 1.2 Psoriatic Arthritis SK…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 0074-7040

What is NDC 0074-7040?
0074-7040 is the product NDC for Skyrizi (risankizumab-rzaa) kit, listed with the FDA by AbbVie Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?
Skyrizi (Risankizumab-rzaa).
Who is the labeler?
AbbVie Inc., NDC labeler code 0074. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Skyrizi?
9 other product NDCs are listed under this name. See all Skyrizi NDCs.
Is there a related HCPCS / J-code?
Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Skyrizi NDCs
ProductStrengthForm · routeLabelerProduct NDCPackage NDCs (11-digit)
Skyrizirisankizumab-rzaaRisankizumab 55 mg/.37mLInjection, SolutionSubcutaneousAbbVie Inc.0074-405900074-4059-0100074-4059-71
Skyrizirisankizumab-rzaaRisankizumab 180 mg/1.2mLInjectionSubcutaneousAbbVie Inc.0074-830000074-8300-01
Skyrizirisankizumab-rzaaRisankizumab 180 mg/1.2mLInjectionSubcutaneousAbbVie Inc.0074-835000074-8350-01
Skyrizirisankizumab-rzaa—KitAbbVie Inc.0074-704200074-7042-04
Skyrizirisankizumab-rzaa—KitIntravenousAbbVie Inc.0074-106500074-1065-0100074-1065-02
Skyrizirisankizumab-rzaaRisankizumab 600 mg/10mLInjectionIntravenousAbbVie Inc.0074-501500074-5015-0100074-5015-02
Skyrizirisankizumab-rzaa—KitIntravenousAbbVie Inc.0074-107000074-1070-0100074-1070-02
Skyrizirisankizumab-rzaaRisankizumab 150 mg/mLInjectionSubcutaneousAbbVie Inc.0074-210000074-2100-0100074-2100-70
Skyrizirisankizumab-rzaaRisankizumab 150 mg/mLInjectionSubcutaneousAbbVie Inc.0074-105000074-1050-0100074-1050-70

Other NDCs under BLA 761105

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under BLA 761105
ProductStrengthForm · routeLabelerProduct NDC
Skyrizirisankizumab-rzaa—KitIntravenousAbbVie Inc.0074-1070
Skyrizirisankizumab-rzaaRisankizumab 180 mg/1.2mLInjectionSubcutaneousAbbVie Inc.0074-8300
Skyrizirisankizumab-rzaaRisankizumab 150 mg/mLInjectionSubcutaneousAbbVie Inc.0074-2100
Skyrizirisankizumab-rzaaRisankizumab 180 mg/1.2mLInjectionSubcutaneousAbbVie Inc.0074-8350
Skyrizirisankizumab-rzaa—KitAbbVie Inc.0074-7042
Skyrizirisankizumab-rzaa—KitIntravenousAbbVie Inc.0074-1065
Skyrizirisankizumab-rzaaRisankizumab 150 mg/mLInjectionSubcutaneousAbbVie Inc.0074-1050
Skyrizirisankizumab-rzaaRisankizumab 55 mg/.37mLInjection, SolutionSubcutaneousAbbVie Inc.0074-4059

Med-Code uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free Med-Code account to keep looking up NDCs, J-codes and drugs.

Create a free accountLog in
Skyrizi NDC 0074-7040 | National Drug Code | Med-Code